Table 3.
Study characteristics of animal intervention studies assessing the impact of red wine polyphenols on vascular health and function
| Authors | Year | Animal | Disease/clinical model | Supplement | Dosage (mg/kg/day) | Duration | Measure | Healthy effect (sig) | Disease effect (sig) |
|---|---|---|---|---|---|---|---|---|---|
| Akar et al. | 2011 | Rabbit | T2D | Resveratrol | 5 (mg/l) | (8–10 weeks) | EVVR | Yes | |
| Akar et al. | 2012 | Rat | FVD | Resveratrol | 50 (mg/l) | (10 weeks) | EVVR | Yes | |
| Aribal-Kocatuerk et al. | 2009 | Rat | None | Resveratrol | 20 | (24 weeks) | SBP | Yes | |
| Aubin et al. | 2008 | Rat | HF | Resveratrol | 20 | (8 weeks) | SBP | No | Yes |
| Bernatova et al. | 2002 | Rat | L-NAME | Provinols | 2.5 | (1–3 weeks) | SBP and EVVR | Yes | |
| Behbahani et al. | 2016 | Rat | SH | Resveratrol | 40 | (10 weeks) | EVVR and BP | No | Yes |
| Bhatt et al. | 2011 | Rat | SH | Resveratrol | 5 | (10 weeks) | SBP | Yes | |
| Biala et al. | 2010 | Rat | Transgenic (Human Renin and angiotensin) | Resveratrol | 800 | (4 weeks) | SBP | No | Yes |
| Cheng et al. | 2016 | Rat | FVD | Resveratrol | 10 | (1 week) | BP | Yes | |
| Cheng et al. | 2013 | Rat | FVD | Resveratrol | 10 | (2–4 weeks) | SBP and EVVR | Yes | |
| Cheserek et al. | 2016 | Mouse | HFD | Resveratrol (and quercetin) | 60 + 10 (g/kg chow) | (26 weeks) | EVVR | Yes | |
| da Luz et al. | 2011 | Rat | None | Resveratrol | 4 (mg/kg chow) | (4 weeks) | EVVR | No | |
| Dal-Ros et al. | 2012 | Rat | Ageing | RWP | 100 | (4 weeks) | BP and FMD | Yes | |
| Dolinsky et al. | 2013 | Rat and Mouse | SH | Resveratrol |
146 (rat) 320 (mice) |
(5 weeks) | EVVR | Yes | |
| Franco et al. | 2013 | Rat | Obese | Resveratrol | 30 | (30 days) | BP | Yes | |
| Gendron et al. | 2012 | Mouse | Ageing | ( +)-Catechin | 0.75 | (12–36 weeks) | EVVR | Yes | Yes |
| Gocmez et al. | 2016 | Rat | Ageing | Resveratrol | 15 | (2 weeks) | SBP and EVVR | No | Yes |
| Gordish et al. | 2016 | Rat | SH | Resveratrol | 146 | (4 weeks) | BP | No | Yes |
| Hort et al. | 2012 | Mouse | Transgenic (LDL Receptor) | RWE | 3–30 | (3 months) | BP | Yes | |
| Inanaga et al. | 2009 | Mouse | AngII induced IL-6 expression | Resveratrol | 10 | (2 and 4 weeks) | BP | No | Yes |
| Jang et al. | 2015 | Rat | SH | GSE | 15–30 | (8 weeks) | SBP and EVVR | Yes | |
| Jendekova et al. | 2006 | Rat | L-NAME | Provinols | 40 | (4 or 7 weeks) | SBP | Yes | |
| Jiminez et al. | 2007 | Rat | SH | RWP | 40 | (5 weeks) | EVVR | No | Yes |
| Kavas et al. | 2013 | Rat | None | Resveratrol | 20 | (6 weeks) | BP | Yes | No |
| Khodja et al. | 2012 | Rat | Ageing | RWP | 100 | (2 or 4 weeks) | BP | No | Yes |
| Kosuru et al. | 2018 | Rat | FVD | Pterostilbene | 20 | (8 weeks) | EVVR | No | Yes |
| Lee et al. | 2017 | Rat | Spontaneous Heart Failure | Resveratrol or pterostilbene | 2.5 | (8 weeks) | SBP | No | Yes |
| Louis et al. | 2012 | Rat | Obese | Resveratrol | 2.5 | (4 weeks) | SBP | No | Yes |
| Majumdar et al. | 2013 | Rat | Ovariectomy-induced VD (+ tobacco extract) | Resveratrol | 50 | (8 weeks) | BP and CBF | No | Yes |
| Miatello et al. | 2005 | Rat | FVD | Resveratrol | 10 | (12 weeks) | SBP and EVVR | No | Yes |
| Mizutani et al. | 2000 | Rat | SH | Resveratrol | 5 | (8 weeks) | EVVR | Yes | |
| Mizutani et al. | 2001 | Rat | SH | Resveratrol | 1 | (8 weeks) | SBP | No | |
| Moraloglu et al. | 2012 | Rat | DOCA-Preclampsia | Resveratrol | 20 | (16 weeks) | SBP | No | |
| Mozafari et al. | 2015 | Rat | T2D | Resveratrol | 5–20 | (4 weeks) | SBP and EVVR | Yes | |
| Ozan et al. | 2017 | Rat | FVD | Resveratrol | 10 | (8 weeks) | BP and EVVR | No | Yes |
| Phyu et al. | 2016 | Rat | T2D | Resveratrol | 2 | (8 weeks) | SBP | Yes | Yes |
| Puzserova et al. | 2006 | Rat | Stressed | Provinols | 20 | (8 weeks) | SBP | Yes | No |
| Rezzani et al. | 2009 | Rat | Nephrotoxicity | Provinols | 40 | (3 weeks) | DBP and EVVR | No | Yes |
| Rivera et al. | 2009 | Rat | Obese | Resveratrol | 10 | (8 weeks) | SBP and EVVR | No | Yes |
| Robich et al. | 2010 | Swine | Hypercholesterolemic | Resveratrol | 100 | (11 weeks) | SBP | Yes | |
| Rush et al. | 2007 | Rat | SH | Resveratrol | 0.488–4.48 (mg/l) | (4 weeks) | BP and CBF | Yes | |
| Soylemez et al. | 2009 | Rat | None | Resveratrol | 50 (mg/l) | (3 weeks) | SBP | Yes | |
| Thandapily et al. | 2010 | Rat | SH | Resveratrol | 2.5 | (10 weeks) | EVVR | No | No |
| Toth et al. | 2014 | Mouse | Ageing | Resveratrol | 200 | (10 days) | BP | No | Yes |
| Toth et al. | 2015 | Mouse | Ageing + Hypertensive | Resveratrol | 200 | (10 days) | FMD | No | |
| Ungvari et al. | 2010 | Mouse | Transgenic + HFVD | Resveratrol | 2.4 (g/kg chow) | (16 weeks) | BP and EVVR | Yes | |
| Wang et al. | 2018 | Mouse | T2D | Resveratrol | 10 | (4–24 weeks) | SBP | No | Yes |
Type 2 diabetes (T2D), high fructose vascular dysfunction (FVD), high fat diet (HFD), spontaneously hypertensive (SH), L-NAME induced vascular dysfunction (L-NAME), ex vivo vascular responsiveness (EVVR), systolic blood pressure (SBP), blood pressure (BP), flow mediated dilation (FMD), cerebrovascular blood flow (CBF)